Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
7.17
-0.11 (-1.51%)
Aug 14, 2025, 11:45 AM - Market open

Xeris Biopharma Holdings Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2016 - 2019
Period Ending
Aug '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
Market Capitalization
1,158505325181365-
Upgrade
Market Cap Growth
124.21%55.70%79.47%-50.50%--
Upgrade
Enterprise Value
1,354707487226360-
Upgrade
Last Close Price
7.283.392.351.332.93-
Upgrade
PS Ratio
4.512.491.981.647.37-
Upgrade
PB Ratio
--17.07-47.864.003.84-
Upgrade
EV/Sales Ratio
5.503.482.972.057.26-
Upgrade
Debt / Equity Ratio
-13.32-9.17-33.794.380.932.58
Upgrade
Asset Turnover
0.740.630.490.340.210.15
Upgrade
Inventory Turnover
0.790.850.901.061.011.77
Upgrade
Quick Ratio
1.181.121.172.081.524.99
Upgrade
Current Ratio
1.951.671.642.541.805.40
Upgrade
Return on Equity (ROE)
---324.20%-134.83%-190.28%-378.20%
Upgrade
Return on Assets (ROA)
-0.70%-5.33%-8.25%-15.78%-28.45%-38.02%
Upgrade
Return on Capital (ROIC)
-0.95%-7.42%-11.81%-24.01%-43.37%-52.67%
Upgrade
Earnings Yield
-2.77%-10.85%-19.18%-52.34%-33.59%-
Upgrade
FCF Yield
-1.45%-7.49%-15.18%-57.18%-26.44%-
Upgrade
Buyback Yield / Dilution
-8.03%-6.61%-1.51%-71.62%-85.32%-63.32%
Upgrade
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q